{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:37:53Z","timestamp":1780418273832,"version":"3.54.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010438","name":"Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu","doi-asserted-by":"publisher","award":["502-01-33114230-03592"],"award-info":[{"award-number":["502-01-33114230-03592"]}],"id":[{"id":"10.13039\/501100010438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.biopha.2020.110530","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T12:28:41Z","timestamp":1595507321000},"page":"110530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol"],"prefix":"10.1016","volume":"130","author":[{"given":"Agnieszka","family":"Karbownik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi\u0142osz","family":"Miedziaszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Stanis\u0142awiak-Rudowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Ja\u017awiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wolc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Grze\u015bkowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Sza\u0142ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110530_bib0005","doi-asserted-by":"crossref","first-page":"50","DOI":"10.21037\/cco.2018.10.10","article-title":"Systemic therapy for hepatocellular carcinoma: beyond sorafenib","volume":"7","author":"Boland","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110530_bib0010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/FPC.0000000000000279","article-title":"PhamGKB summary: sorafenib pathways","volume":"27","author":"Gong","year":"2017","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.biopha.2020.110530_bib0015","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s12276-018-0159-1","article-title":"Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors","volume":"50","author":"M\u00e9ndez-Blanco","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2020.110530_bib0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ijpharm.2019.05.064","article-title":"Development of sorafenib loaded nanoparticles to improve oral bioavailability using a quality by design approach","volume":"566","author":"Park","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2020.110530_bib0025","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1158\/1078-0432.CCR-12-1967","article-title":"Ontogeny and sorafenib metabolism","volume":"18","author":"Zimmerman","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2020.110530_bib0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1620\/tjem.237.173","article-title":"Monitoring serum levels of sorafenib and its N-Oxide is essential for long-term sorafenib treatment of patients with hepatocellular carcinoma","volume":"237","author":"Shimada","year":"2015","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.biopha.2020.110530_bib0035","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2017.01.002","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia","volume":"129","author":"Miners","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110530_bib0040","doi-asserted-by":"crossref","first-page":"113616","DOI":"10.1016\/j.bcp.2019.08.018","article-title":"Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202","volume":"169","author":"Korprasertthaworn","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110530_bib0045","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s12276-018-0159-1","article-title":"Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors","volume":"50","author":"M\u00e9ndez-Blanco","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.biopha.2020.110530_bib0050","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12943-016-0526-2","article-title":"Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib","volume":"15","author":"Houessinon","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2020.110530_bib0055","doi-asserted-by":"crossref","first-page":"6614","DOI":"10.1002\/cam4.2549","article-title":"Racial disparities in alpha-fetoprotein testing and alpha-fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.biopha.2020.110530_bib0060","first-page":"919","article-title":"Important and relevant symptoms including pain concerns in hepatocellular carcinoma (HCC): a patient interview study","volume":"22","author":"Kaiser","year":"2014","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.biopha.2020.110530_bib0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/JHC.S145450","article-title":"Hepatocellular cancer pain: impact and management challenges","volume":"5","author":"Christian-Miller","year":"2018","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.biopha.2020.110530_bib0070","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.pharep.2018.01.005","article-title":"Tapentadol - A representative of a new class of MOR-NRI analgesics","volume":"70","author":"Zaj\u0105czkowska","year":"2018","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.biopha.2020.110530_bib0075","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s13346-018-0524-6","article-title":"Improving the oral bioavailability of tapentadol via a carbamate prodrug approach: synthesis, bioactivation, and pharmacokinetics","volume":"8","author":"Li","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.biopha.2020.110530_bib0080","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejp.1196","article-title":"Comparative pharmacology and toxicology of tramadol and tapentadol","volume":"22","author":"Faria","year":"2018","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.biopha.2020.110530_bib0085","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/03602532.2016.1229788","article-title":"Comparative metabolism of tramadol and tapentadol: a toxicological perspective","volume":"48","author":"Barbosa","year":"2016","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.biopha.2020.110530_bib0090","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1080\/13880209.2017.1340963","article-title":"The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism","volume":"55","author":"Wang","year":"2017","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.biopha.2020.110530_bib0095","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/21691401.2016.1163713","article-title":"Bio-fabrication and statistical optimization of polysorbate 80 coated chitosan nanoparticles of tapentadol hydrochloride for central antinociceptive effect: in vitro-in vivo studies","volume":"45","author":"Patil","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.biopha.2020.110530_bib0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jchromb.2004.06.003","article-title":"Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum","volume":"809","author":"Afify","year":"2004","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.biopha.2020.110530_bib0105","doi-asserted-by":"crossref","first-page":"e96664","DOI":"10.1371\/journal.pone.0096664","article-title":"Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient","volume":"9","author":"Ye","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110530_bib0110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ijcp.12352","article-title":"GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib): second interim analysis","volume":"68","author":"Lencioni","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.biopha.2020.110530_bib0115","first-page":"1","article-title":"Sorafenib for patients with hepatocellular carcinoma and child-pugh B liver cirrhosis: lessons learned from a terminated study","volume":"24","author":"Labeur","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2020.110530_bib0120","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.canlet.2019.03.030","article-title":"Epigenetic regulation of UDP-Glucuronosyltransferase by microRNA-200a\/-183: implications for responses to sorafenib treatment in patients with hepatocellular carcinoma","volume":"454","author":"Ge","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2020.110530_bib0125","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejca.2017.09.003","article-title":"Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: validation study and biological rationale","volume":"86","author":"Casadei Gardini","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110530_bib0130","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1517\/17425255.2015.1030392","article-title":"Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib","volume":"11","author":"Tlemsani","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.biopha.2020.110530_bib0135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","article-title":"Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib","volume":"43","author":"Mross","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110530_bib0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00280-009-1096-4","article-title":"UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib","volume":"65","author":"Meza-Junco","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110530_bib0145","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1200\/JCO.2008.20.0931","article-title":"Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301","volume":"27","author":"Miller","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110530_bib0150","first-page":"40","article-title":"Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis","volume":"4","author":"Abou-Alfa","year":"2011","journal-title":"Gastrointest. Cancer Res."},{"key":"10.1016\/j.biopha.2020.110530_bib0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2006.08.032","article-title":"Results from an in vitro and a clinical\/pharmacological phase I study with the combination irinotecan and sorafenib","volume":"43","author":"Mross","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110530_bib0160","series-title":"Australian Public Assessment Report for T Apentado","author":"Palexia","year":"2020"},{"key":"10.1016\/j.biopha.2020.110530_bib0165","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1248\/bpb.b13-00899","article-title":"Effect of adrenalectomy on expression and induction of UDP-glucuronosyltransferase 1A6 and 1A7 in rats","volume":"37","author":"Sakakibara","year":"2014","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.biopha.2020.110530_bib0170","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/jps.2600630645","article-title":"Urinary excretion of acetaminophen by the rat","volume":"63","author":"Miller","year":"1974","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2020.110530_bib0175","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF01061867","article-title":"Pharmacokinetic study of the fate of acetaminophen and its conjugates in rats","volume":"11","author":"Watari","year":"1983","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.biopha.2020.110530_bib0180","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/11589080-000000000-00000","article-title":"Tapentadol in pain management: a \u03bc-opioid receptor agonist and noradrenaline reuptake inhibitor","volume":"25","author":"Hartrick","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopha.2020.110530_bib0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/187231208783478434","article-title":"Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes","volume":"2","author":"Kneip","year":"2008","journal-title":"Drug Metab. Lett."},{"key":"10.1016\/j.biopha.2020.110530_bib0190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1592\/phco.30.1.25","article-title":"Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies","volume":"30","author":"Smit","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.biopha.2020.110530_bib0195","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.ejca.2012.10.016","article-title":"Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors","volume":"49","author":"Simonelli","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110530_bib0200","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.transproceed.2011.06.063","article-title":"Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports","volume":"43","author":"Takahara","year":"2011","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.biopha.2020.110530_bib0205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00280-011-1674-0","article-title":"A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine","volume":"69","author":"Infante","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110530_bib0210","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1159\/000491058","article-title":"Melatonin synergizes with sorafenib to suppress pancreatic Cancer via melatonin receptor and PDGFR-\u03b2\/STAT3 pathway","volume":"47","author":"Fang","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.biopha.2020.110530_bib0215","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.biopha.2017.11.006","article-title":"Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN\/Akt signaling pathway","volume":"97","author":"Lu","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2020.110530_bib0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejphar.2018.05.027","article-title":"Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3\/ERK\/AKT","volume":"832","author":"Mao","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110530_bib0225","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3892\/or.2015.4181","article-title":"Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis","volume":"34","author":"Zhong","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2020.110530_bib0230","doi-asserted-by":"crossref","first-page":"e65569","DOI":"10.1371\/journal.pone.0065569","article-title":"Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells","volume":"8","author":"Cervello","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110530_bib0235","article-title":"Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma","volume":"8","author":"Lu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110530_bib0240","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1089\/thy.2017.0085","article-title":"No effect of levothyroxine and levothyroxine-induced subclinical thyrotoxicosis on the pharmacokinetics of sorafenib in healthy male subjects","volume":"27","author":"Huang","year":"2017","journal-title":"Thyroid"},{"key":"10.1016\/j.biopha.2020.110530_bib0245","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/00498254.2015.1109160","article-title":"The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4","volume":"46","author":"Wang","year":"2016","journal-title":"Xenobiotica."},{"key":"10.1016\/j.biopha.2020.110530_bib0250","series-title":"INN-Sorafenib \u2013 European Medicines Agency. Scientific Discussion","author":"Nexavar","year":"2020"},{"issue":"2010","key":"10.1016\/j.biopha.2020.110530_bib0255","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1586\/ern.10.72","article-title":"Tapentadol immediate-release for acute pain","volume":"10","author":"Hartrick","year":"2010","journal-title":"Expert Rev. Neurother."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222030723X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222030723X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T18:20:43Z","timestamp":1766082043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222030723X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":51,"alternative-id":["S075333222030723X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110530","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110530","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110530"}}